Anti-VEGF conbercept developed for AMD treatment

MIAMI — Phase 3 PHOENIX study data show a strong anatomic benefit of conbercept treatment, an anti-VEGF developed in China, a speaker said here. “There is a strong benefit of conbercept treatment on anatomic outcomes that support the visual acuity results for neovascular AMD,” Ronald P. Danis, MD, said at the Angiogenesis, Exudation, and Degeneration 2014 meeting. Conbercept was approved for use in China for age-related macular degeneration in December.

Full Story →